LB PHARMACEUTICALS INC

LB Pharmaceuticals (LBRX) showed no cyber incidents or red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability over this recent period. However, a compressed timeframe captures limited signal; the full SEC analysis Report extends review to 12 months of filings, adds a dilution risk score based on capital structure and equity issuance trends, and flags financing history and AI-detected risk signals that shorter windows may miss. The full $49 Report provides quantified dilution risk, complete 8-K context, and forward-looking signal analysis that plain absence of recent events does not replace.